Immune Checkpoint Inhibitor-Associated Colitis: From Mechanism to Management

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2022 Jan 7

PMID 34992611

Citations 48

Authors

Liansha Tang

Jialing Wang

Nan Lin

Yuwen Zhou

Wenbo He

Jiyan Liu

Xuelei Ma

Affiliations

Soon will be listed here.

Abstract

Immune checkpoint inhibitors (ICIs), as one of the innovative types of immunotherapies, including programmed cell death-1 (PD-1), programmed cell death-ligand 1 (PD-L1), and cytotoxic T lymphocyte antigen 4 (CTLA-4) inhibitors, have obtained unprecedented benefit in multiple malignancies. However, the immune response activation in the body organs could arise immune-related adverse events (irAEs). Checkpoint inhibitor colitis (CIC) is the most widely reported irAEs. However, some obscure problems, such as the mechanism concerning gut microbiota, the confusing differential diagnosis with inflammatory bowel disease (IBD), the optimal steroid schedule, the reintroduction of ICIs, and the controversial prognosis features, influence the deep understanding and precise diagnosis and management of CIC. Herein, we based on these problems and comprehensively summarized the relevant studies of CIC in patients with NSCLC, further discussing the future research direction of this specific pattern of irAEs.

Citing Articles

Development and validation of a nomogram for predicting immune-mediated colitis in lung cancer patients treated with immune checkpoint inhibitors: a retrospective cohort study in China.

Xu Q, Li X, Yuan Y, Liang G, Hu Z, Zhang W Front Immunol. 2025; 16:1510053.

PMID: 39949779 PMC: 11821966. DOI: 10.3389/fimmu.2025.1510053.

Gut Microbiota-Tumor Microenvironment Interactions: Mechanisms and Clinical Implications for Immune Checkpoint Inhibitor Efficacy in Cancer.

Said S, Ibrahim W Cancer Manag Res. 2025; 17:171-192.

PMID: 39881948 PMC: 11776928. DOI: 10.2147/CMAR.S405590.

New insight in immunotherapy and combine therapy in colorectal cancer.

Ji K, Jia H, Liu Z, Yu G, Wen R, Zhang T Front Cell Dev Biol. 2025; 12():1453630.

PMID: 39839672 PMC: 11747282. DOI: 10.3389/fcell.2024.1453630.

Treatment of immune checkpoint inhibitor-related colitis: a narrative review.

Wang S, Wang H Transl Cancer Res. 2025; 13(12):7002-7014.

PMID: 39816545 PMC: 11729759. DOI: 10.21037/tcr-24-2150.

Incidence and risk factors of immune checkpoint inhibitor-induced colitis in Korean patients with cancer.

Kim T, Lee H, Kim E Korean J Intern Med. 2025; 40(1):49-56.

PMID: 39778525 PMC: 11725480. DOI: 10.3904/kjim.2024.135.

References

Gobbini E, Toffart A, Perol M, Assie J, Duruisseaux M, Coupez D . Immune Checkpoint Inhibitors Rechallenge Efficacy in Non-Small-Cell Lung Cancer Patients. Clin Lung Cancer. 2020; 21(5):e497-e510. DOI: 10.1016/j.cllc.2020.04.013. View

Kartolo A, Holstead R, Khalid S, Emack J, Hopman W, Baetz T . Safety of Immunotherapy Rechallenge After Immune-related Adverse Events in Patients With Advanced Cancer. J Immunother. 2020; 44(1):41-48. DOI: 10.1097/CJI.0000000000000337. View

Abu-Sbeih H, Herrera L, Tang T, Altan M, Chaftari A, Okhuysen P . Impact of antibiotic therapy on the development and response to treatment of immune checkpoint inhibitor-mediated diarrhea and colitis. J Immunother Cancer. 2019; 7(1):242. PMC: 6729015. DOI: 10.1186/s40425-019-0714-x. View

Alhatem A, Patel K, Eriksen B, Bukhari S, Liu C . Nivolumab-Induced Concomitant Severe Upper and Lower Gastrointestinal Immune-Related Adverse Effects. ACG Case Rep J. 2020; 6(11):e00249. PMC: 7145206. DOI: 10.14309/crj.0000000000000249. View

Park R, Lopes L, Saeed A . Outcomes following immunotherapy re-challenge after immune-related adverse event: systematic review and meta-analysis. Immunotherapy. 2020; 12(16):1183-1193. DOI: 10.2217/imt-2020-0103. View

Durrechou Q, Domblides C, Sionneau B, Lefort F, Quivy A, Ravaud A . Management of Immune Checkpoint Inhibitor Toxicities. Cancer Manag Res. 2020; 12:9139-9158. PMC: 7533913. DOI: 10.2147/CMAR.S218756. View

Verschuren E, van den Eertwegh A, Wonders J, Slangen R, van Delft F, van Bodegraven A . Clinical, Endoscopic, and Histologic Characteristics of Ipilimumab-Associated Colitis. Clin Gastroenterol Hepatol. 2016; 14(6):836-842. DOI: 10.1016/j.cgh.2015.12.028. View

Marthey L, Mateus C, Mussini C, Nachury M, Nancey S, Grange F . Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease. J Crohns Colitis. 2016; 10(4):395-401. PMC: 4946758. DOI: 10.1093/ecco-jcc/jjv227. View

Pernot S, Ramtohul T, Taieb J . Checkpoint inhibitors and gastrointestinal immune-related adverse events. Curr Opin Oncol. 2016; 28(4):264-8. DOI: 10.1097/CCO.0000000000000292. View

10.

Abu-Sbeih H, Ali F, Wang X, Mallepally N, Chen E, Altan M . Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor-induced colitis. J Immunother Cancer. 2019; 7(1):93. PMC: 6444537. DOI: 10.1186/s40425-019-0577-1. View

11.

Chen J, Pezhouh M, Lauwers G, Masia R . Histopathologic Features of Colitis Due to Immunotherapy With Anti-PD-1 Antibodies. Am J Surg Pathol. 2017; 41(5):643-654. DOI: 10.1097/PAS.0000000000000829. View

12.

Gaucher L, Adda L, Sejourne A, Joachim C, Chaby G, Poulet C . Impact of the corticosteroid indication and administration route on overall survival and the tumor response after immune checkpoint inhibitor initiation. Ther Adv Med Oncol. 2021; 13:1758835921996656. PMC: 7923985. DOI: 10.1177/1758835921996656. View

13.

Tarhini A, Zahoor H, Lin Y, Malhotra U, Sander C, Butterfield L . Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma. J Immunother Cancer. 2015; 3:39. PMC: 4570556. DOI: 10.1186/s40425-015-0081-1. View

14.

Collins M, Michot J, Danlos F, Mussini C, Soularue E, Mateus C . Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies. Ann Oncol. 2017; 28(11):2860-2865. DOI: 10.1093/annonc/mdx403. View

15.

Chaput N, Lepage P, Coutzac C, Soularue E, Le Roux K, Monot C . Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann Oncol. 2019; 30(12):2012. DOI: 10.1093/annonc/mdz224. View

16.

Kunogi Y, Tominaga K, Abe K, Kanazawa M, Tanaka T, Watanabe S . Refractory Immune Checkpoint Inhibitor-Induced Colitis Improved by Tacrolimus: A Case Report. Healthcare (Basel). 2021; 9(4). PMC: 8066945. DOI: 10.3390/healthcare9040418. View

17.

Naidoo J, Nishino M, Patel S, Shankar B, Rekhtman N, Illei P . Immune-Related Pneumonitis After Chemoradiotherapy and Subsequent Immune Checkpoint Blockade in Unresectable Stage III Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2020; 21(5):e435-e444. DOI: 10.1016/j.cllc.2020.02.025. View

18.

Tivol E, Borriello F, Schweitzer A, Lynch W, Bluestone J, Sharpe A . Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity. 1995; 3(5):541-7. DOI: 10.1016/1074-7613(95)90125-6. View

19.

Grover S, Dougan M, Tyan K, Giobbie-Hurder A, Blum S, Ishizuka J . Vitamin D intake is associated with decreased risk of immune checkpoint inhibitor-induced colitis. Cancer. 2020; 126(16):3758-3767. PMC: 7381363. DOI: 10.1002/cncr.32966. View

20.

Abu-Sbeih H, Ali F, Luo W, Qiao W, Raju G, Wang Y . Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis. J Immunother Cancer. 2018; 6(1):95. PMC: 6156850. DOI: 10.1186/s40425-018-0411-1. View